Multiple Myeloma: Cutting-Edge Induction and Maintenance Therapies Lead to Improved Response Rates and Survival for Newly Diagnosed Patients

Multiple Myeloma: Cutting-Edge Induction and Maintenance Therapies Lead to Improved Response Rates and Survival for Newly Diagnosed Patients

Take a deep dive into therapy options for newly diagnosed myeloma patients: whether three drugs are better than two, the case for lenalidomide maintenance therapy, the many improvements in induction treatment, the future of immunotherapy, and more.


Published

May 23, 2018

Created by

UCSF MedConnection

Related Presenters

Nina Shah, MD

Nina Shah, MD

Hematologist Oncologist

Dr. Nina Shah is a hematologist who specializes in the treatment of multiple myeloma, a type of cancer affecting the blood marrow.

View profile